Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037. Vividion is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG.

Cells are capable of translating mechanical changes into biological responses. This process is known as mechanotransduction and plays a fundamental role in the progression of solid tumors, such as breast cancer.

It is well-established that a common mechanical alteration in cancer progression involves tissue hardening.

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery? 9/15/2023

RayzeBio’s $311M, Neumora’s $250M IPOs Among Biotech’s Largest This Year 9/15/2023

Anavex’s Blarcamesine Slows Cognitive Decline in Alzheimer’s Patients 9/15/2023

Novartis Shareholders Approve Sandoz Spin-Off as Product Plans Increase 9/15/2023

AstraZeneca’s Alexion Reaches $125M Settlement in Soliris Sales Lawsuit 9/15/2023

5 Key Regulatory Guidance Documents Issued in 2023 9/15/2023

GSK and Save the Children have announced today that they are renewing their award-winning partnership for a further five years. GSK will invest £15 million in the partnership with Save the Children and they will work together to increase child vaccination rates, with a focus on reducing the number of 'zero dose' children in Ethiopia and Nigeria.

Biopharma Career Fairs Make a Powerful Comeback 9/14/2023

Postdoc Programs at Pharmaceutical Companies: A Research Path Less Chosen 9/14/2023

Scientists from the German Cancer Research Center (DKFZ) identify a new and surprising function of a membrane protein on the surface of cancer cells: It supports and stabilizes an important "co-stimulatory" factor that enhances the activation of T cells, thus improving the immune response against the tumor. The study was conducted in collaboration with researchers from the Netherlands Cancer Institute.

Moderna Scales Back COVID Vaccine Production, Pursues mRNA Medicines Plan 9/13/2023

Eiger Discontinues Phase III Hepatitis Study Due to Safety Concerns 9/13/2023

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial 9/13/2023

Neurocrine’s Congenital Adrenal Hyperplasia Candidate Clears Phase III 9/13/2023

Why Biopharma Companies Buy Stock in One Another 9/13/2023

Opinion: Building a Global Presence on Both Sides of the Pond 9/13/2023

The Top 12 Biopharma Companies Hiring Now 9/13/2023

A natural compound found in the culinary spice turmeric may be as effective as omeprazole - a drug used to curb excess stomach acid - for treating indigestion symptoms, suggests the first study of its kind, published online in the journal BMJ Evidence-Based Medicine.

Turmeric is derived from the root of the Curcuma longa plant. It contains a naturally active compound called curcumin thought to have anti-inflammatory and antimicrobial properties, and has long been used as a medicinal remedy, including for the treatment of indigestion, in South East Asia.